What's new? Log in Free sign up

Evotec SE (EVO)

Company Profile

Company profile

Ticker

EVO, EVOTF

Exchange

Website

CEO

Dr. Christian Wojczewski

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

EVO stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

Evotec announces change in Management Board

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014

Current report (foreign)

Results of the Annual General Meeting 2024

Current report (foreign)

Notice of late annual filing (foreign)

Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

Current report (foreign)

Evotec announces CEO transition

Transcripts

Earnings call transcript

Latest ownership filings

Excalibur LuxCo SARL

Novo Holdings A/S

Novo Holdings A/S

Novo Holdings A/S

Mubadala Investment Co PJSC

Financial summary

Financial statements Chart EVO financial data

Quarter (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Evotec SE earnings reports.

Institutional ownership, Q2 2024

EVO institutional ownership history Ownership history

6.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	29	21	+38.1%
Opened positions	11	7	+57.1%
Closed positions	3	10	-70.0%
Increased positions	11	6	+83.3%
Reduced positions	2	5	-60.0%

13F shares	Current	Prev Q	Change
Total value	106.17 bn	38.89 bn	+173.0%
Total shares	22.12 mm	4.97 mm	+345.2%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Novo Holdings A/S	14.83 mm	$71.18 bn	NEW
Mubadala Investment Co PJSC	4.60 mm	$22.07 bn	0.0%
Wellington Management	2.03 mm	$9.75 bn	NEW
Millennium Management	191.53 k	$919.33 mm	+131.3%
MS Morgan Stanley	121.81 k	$584.69 mm	+39.0%
DCF Advisers	114.95 k	$551.77 mm	+140.5%
BLK BlackRock	82.60 k	$396.47 mm	+119.7%
GS The Goldman Sachs Group, Inc.	64.86 k	$311.31 mm	NEW
JustInvest	19.23 k	$87.09 mm	NEW
Quadrant Capital	14.22 k	$68.24 mm	+125.4%

Largest transactions	Shares	Bought/sold	Change
Novo Holdings A/S	14.83 mm	+14.83 mm	NEW
Wellington Management	2.03 mm	+2.03 mm	NEW
Millennium Management	191.53 k	+108.71 k	+131.3%
DCF Advisers	114.95 k	+67.16 k	+140.5%
GS The Goldman Sachs Group, Inc.	64.86 k	+64.86 k	NEW
BLK BlackRock	82.60 k	+45.00 k	+119.7%
Optiver Holding B.V.	0.00	-41.51 k	EXIT
MS Morgan Stanley	121.81 k	+34.20 k	+39.0%
Cetera Investment Advisers	0.00	-24.54 k	EXIT
Cetera Advisors	0.00	-24.04 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Evotec And Novo Nordisk Launch First Projects For LAB eN² Accelerator, Focusing On Cardiometabolic Diseases

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global Operations Leadership Team Until A New Organizational Structure Is Designed And Announced In Line With The Strategic Review

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internallyHAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT,

12 Health Care Stocks Moving In Friday's Pre-Market Session

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

Evotec Confirms Review Of Halozyme's Withdrawn EUR 11.00/Share Proposal, Reiterates Confidence In Standalone Growth Strategy

Press releases

From Benzinga Pro

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on

Evotec Announces Change in Management Board

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT,

Comment on Withdrawn Non-Binding Offer

HAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(NASDAQ:EVO)Evotec SE has taken notice of the statement made by

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.